-
aVaxziPen Revolutionizes Vaccine Delivery for Enhanced Accessibility and Distribution
6th June 2023
Originally published in BioStartUps aVaxziPen Ltd, a biotech company developing a novel needle-free vaccine delivery platform, have today announced a partnership to advance the development of two vaccines candidates (one protein and one mRNA-based) using aVaxziPen’s solid dose vaccine-delivery platform, which could help end the need for frozen storage of vaccines, thereby improving equitable access… read more
-
Needle-free vaccine delivery platform aims to end frozen storage needs and improve access
6th June 2023
June 6, 2023; OSLO, Norway and OXFORD, UK: CEPI, the Coalition for Epidemic Preparedness Innovations, and aVaxziPen Ltd, a biotech company developing a novel needle-free vaccine delivery platform, have today announced a partnership to advance the development of two vaccines candidates (one protein and one mRNA-based) using aVaxziPen’s solid dose vaccine-delivery platform, which could help… read more
-
The world has long needed a better vaccine delivery system.” The time of the hollow needle is over – solid dose vaccines are the future
24th May 2023
Originally published by the Medicine Maker I could easily argue that vaccines are the biggest success story of modern medicine; millions of lives are saved across the globe every year through vaccination programs that protect entire populations from a diverse and evolving range of pathogens. Vaccines were already contributing much before COVID-19, but the pandemic demanded… read more
-
aVaxziPen’s needle-free vaccine yields positive data across multiple diseases
18th May 2023
Originally published in LABIOTECH aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, presented data at the World Vaccine Congress (WVC) in Washington, U.S., recently. The company presented a poster entitled, “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models.” The company said immunogenicity data from… read more
-
aVaxziPenTM solid dose vaccines are thermostable compared to liquid vaccines
3rd April 2023
aVaxziPenTM Limited and Sementis Limited have completed a feasibility study formulating vaccinia-based Sementis Copenhagen Vector (SCV) system into aVaxziPen’s solid dose vaccine (SDV), which allows needle-free injection of vaccines using aVaxziPen’s Multi-use pen and disposable cartridge vaccine delivery platform. The study demonstrated that the SDV formulation retained full vaccine titre for at least 12 months… read more
-
aVaxziPen Announces Positive Data in Multiple Diseases on Novel Needle-Free Vaccine, Thermally Stable Delivery Platform at World Vaccine Congress
3rd April 2023
In vivo data demonstrates immune equivalence to traditional needle and syringe injection when using a needle-free solid dose formulation Oxford, UK, 3 April 2023 – aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World Vaccine Congress (WVC) in Washington, USA. The company will present a… read more
